Karnataka's Shilpa Biologics and Alabama's Alveolus Bio sign strategic partnership

Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner.

Logo of Shilpa Medicare and logo of Alveolus Bio / PR Newswire

In a key development, Shilpa Biologics, a Karnataka based Pharmaceutical company, has partnered with Alabama based Alveolus Bio, a respiratory drug development biotech company.

Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner.

As Alveolus Bio gears up for the human clinical trials in the second phase of its live biotherapeutics and small molecule platform, the collaboration would boost manufacturing and reach.

"Securing Shilpa as our lead investor is a transformative step," said Gaurav Mehta, CEO of Alveolus Bio. "Their global pharmaceutical leadership aligns perfectly with our vision to redefine how lung diseases are treated."

Shilpa Medicare brings with it experience in drug discovery, development, and manufacturing, along with strong regulatory capabilities.

ALSO READ: Billionaire Agarwal may invest in US oil service firms to expand Cairn output

Their investment and strategic involvement will accelerate the clinical advancement of Alveolus Bio's resMIT (respiratory microbiota-based inhaled therapeutics) platform. This novel platform enables targeted delivery of inhaled therapies to deep lung regions, addressing unmet needs in diseases such as COPD, Bronchopulmonary Dysplasia (BPD), and Pulmonary Fibrosis.

Dr. C. Vivek Lal, Founder of Alveolus Bio, addressed the potential of the partnership and said, "Alveolus Bio's breakthrough science is poised to transform respiratory care. Through this strategic partnership with Shilpa, we combine disruptive biotech innovation with world-class commercialization, bringing life-changing therapies faster to the market."

"Shilpa has always focused on enabling breakthrough biologics," said Vishnukant Bhutada, Managing Director, Shilpa Medicare.

Bhutada added, "This partnership strengthens our innovation pipeline and reinforces our role as a trusted global partner for biotech development."

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login